Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Chronic Myeloid Leukemia Specialty Channel

Chronic Myeloid Leukemia
Specialty Channel
News
Nilotinib, Dasatinib, or Flumatinib vs Imatinib as Frontline Therapy for Patients With Chronic-Phase Chronic Myeloid Leukemia
03/22/2024

Amber Denham

Amber Denham
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world,...
03/22/2024
Oncology
News
Asciminib Demonstrated Superior Efficacy and Safety Compared to Bosutinib Among Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
06/23/2023

Jordan Kadish

Jordan Kadish
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial...
06/23/2023
Oncology
News
Olverembatinib Well-Tolerated in Adults With TKI-Resistant Chronic Myeloid Leukemia
10/17/2022
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine...
10/17/2022
Oncology
News
FDA Approves Asciminib for Ph+ CML
11/01/2021
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated...
11/01/2021
Oncology
Test Your Knowledge
Quiz: Which of the Following is Not a Standard of Care Treatment Option for CML?
09/10/2021
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a...
09/10/2021
Oncology
Test Your Knowledge
Quiz: Is the Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML?
04/20/2021
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by...
04/20/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment is Considered Gold Standard for CML-CP?
03/16/2021
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of...
03/16/2021
Oncology
Test Your Knowledge
Quiz: Have TKIs Improved the CML Alternative Treatment Landscape?
02/17/2021
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing...
02/17/2021
Oncology
Test Your Knowledge
Quiz: What Was the Outcome of the ASCEMBL Trial?
12/23/2020
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data...
12/23/2020
Oncology
Test Your Knowledge
Quiz: Is Imatinib Considered Gold Standard Frontline Treatment for CML-CP?
11/25/2020
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is...
11/25/2020
Oncology
Test Your Knowledge
Quiz: Is Additional FISH Testing Info in CML Overlooked?
10/28/2020
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns that indicate for complicated chromosomal...
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns that indicate for complicated chromosomal...
True or False: Although FISH...
10/28/2020
Oncology

Advertisement

News

News
Nilotinib, Dasatinib, or Flumatinib vs Imatinib as Frontline Therapy for Patients With Chronic-Phase Chronic Myeloid Leukemia
03/22/2024

Amber Denham

Amber Denham
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world,...
03/22/2024
Oncology
News
Asciminib Demonstrated Superior Efficacy and Safety Compared to Bosutinib Among Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
06/23/2023

Jordan Kadish

Jordan Kadish
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial...
06/23/2023
Oncology
News
Olverembatinib Well-Tolerated in Adults With TKI-Resistant Chronic Myeloid Leukemia
10/17/2022
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine...
10/17/2022
Oncology
News
FDA Approves Asciminib for Ph+ CML
11/01/2021
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated...
11/01/2021
Oncology
News
Generic Version Yields Similar Efficacy, Safety to Imatinib in CML-CP
10/08/2020
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study...
10/08/2020
Oncology
News
Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML
09/29/2020
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2...
09/29/2020
Oncology
News
Michael Mauro, MD, Talks ELN/NCCN Recommendations for Patients With CML
07/18/2020
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates &...
07/18/2020
Oncology
News
Low-Dose TKIs Before Therapy Cessation Leave Treatment-Free Remission Rates Unscathed in CML
06/15/2020
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings...
06/15/2020
Oncology
News
NGS Preferable for Detecting Certain Mutations in Patients With CML
05/14/2020
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS...
05/14/2020
Oncology
News
Switch From Imatinib to Dasatinib May Benefit Certain Patients With CML-CP
05/07/2020
Study findings suggest that switching patients with CML-CP from first-line imatinib to dasatinib may at times be beneficial.
Study findings suggest that switching patients with CML-CP from first-line imatinib to dasatinib may at times be beneficial.
Study findings suggest that...
05/07/2020
Oncology

Interactive Features

Test Your Knowledge
Quiz: Which of the Following is Not a Standard of Care Treatment Option for CML?
09/10/2021
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a...
09/10/2021
Oncology
Test Your Knowledge
Quiz: Is the Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML?
04/20/2021
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by...
04/20/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment is Considered Gold Standard for CML-CP?
03/16/2021
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of...
03/16/2021
Oncology
Test Your Knowledge
Quiz: Have TKIs Improved the CML Alternative Treatment Landscape?
02/17/2021
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing...
02/17/2021
Oncology
Test Your Knowledge
Quiz: What Was the Outcome of the ASCEMBL Trial?
12/23/2020
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data...
12/23/2020
Oncology
Test Your Knowledge
Quiz: Is Imatinib Considered Gold Standard Frontline Treatment for CML-CP?
11/25/2020
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is...
11/25/2020
Oncology
Test Your Knowledge
Quiz: Is Additional FISH Testing Info in CML Overlooked?
10/28/2020
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns that indicate for complicated chromosomal...
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns that indicate for complicated chromosomal...
True or False: Although FISH...
10/28/2020
Oncology
Test Your Knowledge
Quiz: Which Clinical Trial Approved the Use of Imatinib for CML?
09/25/2020
Which clinical trial displayed results that were in favor of imatinib, both in terms of efficacy and tolerability, for chronic myeloid leukemia?
Which clinical trial displayed results that were in favor of imatinib, both in terms of efficacy and tolerability, for chronic myeloid leukemia?
Which clinical trial displayed...
09/25/2020
Oncology
Test Your Knowledge
Quiz: Do Low-Dose TKIs Prior to Therapy Cessation Impair CML Remission Rates?
08/19/2020
True or False: The administration of low-dose TKIs before TKI cessation impairs treatment‐free remission in patients with CML.
True or False: The administration of low-dose TKIs before TKI cessation impairs treatment‐free remission in patients with CML.
True or False: The...
08/19/2020
Oncology
Test Your Knowledge
Quiz: Switching From Imatinib to Dasatinib in Chronic-Phase CML
07/28/2020
True or False: Switching from imatinib to dasatinib, in cases of suboptimal response, may offer clinical benefit in patients with CML.
True or False: Switching from imatinib to dasatinib, in cases of suboptimal response, may offer clinical benefit in patients with CML.
True or False: Switching from...
07/28/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Nilotinib, Dasatinib, or Flumatinib vs Imatinib as Frontline Therapy for Patients With Chronic-Phase Chronic Myeloid Leukemia
03/22/2024

Amber Denham

Amber Denham
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world,...
03/22/2024
Oncology
News
Asciminib Demonstrated Superior Efficacy and Safety Compared to Bosutinib Among Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
06/23/2023

Jordan Kadish

Jordan Kadish
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial...
06/23/2023
Oncology
News
Olverembatinib Well-Tolerated in Adults With TKI-Resistant Chronic Myeloid Leukemia
10/17/2022
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine...
10/17/2022
Oncology
News
FDA Approves Asciminib for Ph+ CML
11/01/2021
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated...
11/01/2021
Oncology
News
Generic Version Yields Similar Efficacy, Safety to Imatinib in CML-CP
10/08/2020
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study...
10/08/2020
Oncology
News
Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML
09/29/2020
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2...
09/29/2020
Oncology
News
Michael Mauro, MD, Talks ELN/NCCN Recommendations for Patients With CML
07/18/2020
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates &...
07/18/2020
Oncology
News
Low-Dose TKIs Before Therapy Cessation Leave Treatment-Free Remission Rates Unscathed in CML
06/15/2020
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings...
06/15/2020
Oncology
News
NGS Preferable for Detecting Certain Mutations in Patients With CML
05/14/2020
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS...
05/14/2020
Oncology
News
Switch From Imatinib to Dasatinib May Benefit Certain Patients With CML-CP
05/07/2020
Study findings suggest that switching patients with CML-CP from first-line imatinib to dasatinib may at times be beneficial.
Study findings suggest that switching patients with CML-CP from first-line imatinib to dasatinib may at times be beneficial.
Study findings suggest that...
05/07/2020
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement